AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2161435
Drug: Prolonged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged therapy with lisinopril (30-45 days)
Trial: 16840744
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 or 5 mg/kg)
Trial: 26861051
Drug: Mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine granules (MG)
Trial: 18390083
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (intramuscular)
Trial: 12505865
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day for 1 month)
Trial: 2142292
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic saline solution
Trial: 28936
Drug: Etilefrine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine (0.25 mg/min)
Trial: 3297521
Drug: No CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CPAP treatment
Trial: 30665439
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1000 mg)
Trial: 25631258
Drug: 2% PQ10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% PQ10 gel
Trial: 21724197
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (high dose)
Trial: 15180757
Drug: omalizumab (>/=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omalizumab (>/= 0.016 mg/kg/IgE [IU/ml] per 4 weeks)
Trial: 7640969
Drug: Functional Standing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Standing Test (FST) administered by two testers
Trial: 7640969
Drug: Functional Standing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Standing Test (FST) administered to adolescents with SCI
Trial: 7640969
Drug: Functional Standing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Standing Test (FST) administered to able-bodied young adults
Trial: 23946328
Drug: CHOP-R (doxorubicin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-R (doxorubicin-based therapy)
Trial: 15181095
Drug: Dihydrotestosterone (DHT)
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (DHT) - daily transdermal, n = 17, for 3 months
Trial: 15181095
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human chorionic gonadotropin (rhCG) - subcutaneous, two injections weekly, n = 20, for 3 months
Trial: 8302148
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous labetalol (1.0‐1.5 mg/Kg, repeated bolus of 10 mg/bolus)
Trial: 24237300
Drug: Interferon-alpha lozenge
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha lozenge 1500 IU/day
Trial: 22398262
Drug: Adding low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding low level laser therapy (LLLT) to ultrasound (US) and exercise
Trial: 10361382
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg in an i.v. bolus injection)
Trial: 7732443
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group managed without radiocontrast material, received a suppository on the third day
Trial: 7037504
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (betamethasone valerate or clobetasone butyrate)
Trial: 30302838
Drug: Knowledge to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge to advise on medications
Trial: 6711601
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid therapy
Trial: 27812547
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide
Trial: 7708638
Drug: Aspirin test
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin test
Trial: 30395011
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Trial: 30395011
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Trial: 30395011
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of IIV4
Trial: 16996784
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of risk factors in oral cancer; 100% identified tobacco as a risk factor.
Trial: 16996784
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of risk factors in oral cancer; 90% identified alcohol as a risk factor.
Trial: 16996784
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of risk factors in oral cancer; 50.7% identified sun exposure with labial cancer.
Trial: 16996784
Drug: Advice on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice on prevention of oral cancer; 51.4% routinely gave advice to patients.
Trial: 16996784
Drug: Self-assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessment of training; 57.1% did not consider themselves sufficiently trained to discover suspected oral cancer lesions.
Trial: 16996784
Drug: Perception of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perception of academic training; 84.3% recognized insufficient academic training on early diagnosis and prevention of oral cancer.
Trial: 2701817
Drug: Intraoperative portal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative portal chemotherapy without blood transfusion
Trial: 28719280
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) - one round
Trial: 28719280
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) - two rounds
Trial: 23503379
Drug: Genetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic therapy combined with reconstructive vascular operations in 35 patients.
Trial: 23503379
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (control group) in 60 patients.
Trial: 18823290
Drug: JNJ-38488502 (0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38488502 (0.42 mg kg(‐1) i.v. infusion)
Trial: 15284373
Drug: 1.20 g
RxNorm normalized name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 1.20 g in 30 g TOPICAL LOTION [Sun Essential]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.20 g protein/(kg. d) for 2 wk (HPro)
Trial: 15284373
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g protein/(kg. d) for 1 wk and then 0.50 g protein/(kg. d) for a 2nd week (IPro)
Trial: 28314555
Drug: Levobupivacain injection
RxNorm normalized name: levobupivacaine Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacain injection (L group)
Trial: 28314555
Drug: Levobupivacain and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacain and magnesium sulfate injection (LM group)
Trial: 26165259
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion through an On Q continuous infusion pump (On Q group)
Trial: 23257347
Drug: Bimosiamose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimosiamose (10 mg) inhaled twice daily for 28 days
Trial: 30734406
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment (FBT-BN)
Trial: 15886245
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg, twice daily)
Trial: 10081536
Drug: Glucose 10%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 10%, 3 ml.kg‐1.h‐1 (300 mg.kg‐1.h‐1)
Trial: 7593729
Drug: Moclobemide 450
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 450 mg three times daily
Trial: 30591028
Drug: Olaratumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaratumab (20 mg/kg, IV infusion) plus liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Trial: 24104699
Drug: Inactivity control
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivity control group (normal daily activities)
Trial: 21094362
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus a β blocker (Group C)
Trial: 21094362
Drug: β blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blocker alone (Group D)
Trial: 17004410
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2) at 1.75 atm abs (n=57)
Trial: 10907671
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (600 ml/day) in healthy volunteers
Trial: 27207107
Drug: Gemcitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) alone
Trial: 22527887
Drug: Pasireotide 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 50 μg sc qd for 14 days
Trial: 22527887
Drug: Pasireotide 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 200 μg sc qd for 14 days
Trial: 22527887
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc qd for 14 days
Trial: 16299240
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral aminopterin, 2 mg/m2, given in two doses 12 hours apart.
Trial: 26960786
Drug: Intramuscular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular therapy of 1 ml Vitamin B12 (2500 mcg) weekly for 6 weeks
Trial: 16239177
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment (no identified underlying aetiology)
Trial: 11452896
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 25 mg acetylsalicylic acid (ASA)
Trial: 10489049
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200 mg dipyridamole (DP)
Trial: 10489049
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 50 mg ASA and 400 mg DP
Trial: 11212158
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg twice daily
Trial: 1924052
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg once daily
Trial: 7117676
Drug: Slow-release frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release frusemide (once-daily)
Trial: 31731368
Drug: TDF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF (300 mg per day)
Trial: 31731368
Drug: ETV +
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV + ADV (0.5 mg + 10 mg per day)
Trial: 27490918
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d soy isoflavones
Trial: 22813645
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy with HIV primary care but ART initiated later
Trial: 5470432
Drug: oral oestrogen-gestogen
RxNorm normalized name: gestodene
DrugBank: Gestodene (DB06730)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral oestrogen-gestogen combination
Trial: 17878473
Drug: Investigational drugs
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drugs or devices
Trial: 28455597
Drug: Digitalis treatment
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis treatment
Trial: 15732025
Drug: Digitalis treatment
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis treatment with propensity analysis
Trial: 12074253
Drug: Egg (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg (640 mg additional dietary cholesterol per day)
Trial: 2183617
Drug: single-dose cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose cephalosporin antibiotic prophylaxis
Trial: 19356621
Drug: FMP2.1/AS02A half-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP2.1/AS02A half-dose (25 microg/0.25 ml)
Trial: 24260195
Drug: Control rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control rabies vaccine
Trial: 19356621
Drug: FMP2.1/AS02A (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP2.1/AS02A (both doses)
Trial: 17644511
Drug: CoQ(10) supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) supplementation (300 mg/day for 1 month)
Trial: 12358921
Drug: Cytotoxic consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic consolidation chemotherapy following tandem transplants (TT)
Trial: 11275293
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration
Trial: 7772356
Drug: Droperidol 300
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol 300 mcg/kg orally
Trial: 29512784
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen gel and oral aspirin combination therapy
Trial: 29512784
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen only therapy
Trial: 19770778
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy after crossover
Trial: 11856388
Drug: Endosseous implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endosseous implant systems (IMZ, Brånemark, Transmandibular)
Trial: 11856388
Drug: Endosseous implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endosseous implant systems (IMZ, Brånemark)
Trial: 11856388
Drug: Transmandibular Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmandibular Implant system
Trial: 10452767
Drug: cetirizine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine 0.25 mg/kg twice daily
Trial: 31335572
Drug: Control (inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (inactivated trivalent influenza vaccine)
Trial: 11092517
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous insulin therapy (PIVIT) in addition to intensive therapy (IT)
Trial: 1957968
Drug: Flunarizine (FLN)
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (FLN) administered as drops in a single evening dose of 5 mg (patients <10 years) or 10 mg (patients >10 years)
Trial: 19813463
Drug: Piroxicam cream
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam cream (1%, applied three times a day)
Trial: 18381903
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole (15 or 30 mg/day)
Trial: 16449030
Drug: Loop diuretics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics, aminoglycosides, neuromuscular blockers (NMB), and vancomycin (50 received vancomycin)
Trial: 16449030
Drug: Cumulative dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dosages and duration of use of diuretics, NMB, vancomycin, and overlap of diuretics with NMB, aminoglycosides, and vancomycin
Trial: 4018467
Drug: Lidocaine (L)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (L) - bolus of 1 mg/kg followed by an infusion of 10 mg/min for 20 minutes and thereafter of 1.5 mg/min
Trial: 4018467
Drug: Amiodarone (A)
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone (A) - bolus of 5 mg/kg and an eventual repeat dose of 150 mg followed by an infusion of 1.8 g/24 h
Trial: 20485707
Drug: Lidocaine (L)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (L)
Trial: 26749407
Drug: Ranolazine 1000mg
RxNorm normalized name: RANOLAZINE 1000MG TAB,SA
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000mg twice daily added to glimepiride
Trial: 26749407
Drug: Ranolazine 1000mg
RxNorm normalized name: RANOLAZINE 1000MG TAB,SA
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000mg twice daily added to metformin
Trial: 23025057
Drug: 24-week peginterferon
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group A)
Trial: 28436395
Drug: Intranasal 200
RxNorm normalized name: Influenza, live, trivalent, intranasal 2009-2010 spray [FluMist]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 200 mg GSH
Trial: 28436395
Drug: Intranasal 100
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 100 mg GSH
Trial: 28431278
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (saline)
Trial: 25251411
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel applied to one-half of the sockets
Trial: 25251411
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no chlorhexidine gel)
Trial: 21281463
Drug: Irinotecan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 80 mg/m2 i.v., LV 200 mg/m2, 5FU 450 mg/m2 bolus (Arm A)
Trial: 21281463
Drug: Leucovorin 200
RxNorm normalized name: leucovorin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 200 mg/m2 and 5FU 500 mg/m2 i.v. bolus (Arm B)
Trial: 16733624
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of calcium daily
Trial: 8155035
Drug: Pentoxifylline at
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline at 2000 mg/d
Trial: 24377455
Drug: Bayberry juice
RxNorm normalized name: bilberry juice extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayberry juice (250 mL twice daily for 4 weeks)
Trial: 29883974
Drug: intralipid/heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intralipid/heparin infusion
Trial: 18343810
Drug: Transvaginal aspiration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal aspiration of hydrosalpinx under antibiotics cover
Trial: 31563697
Drug: Letrozole (LE)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LE) combined with low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol
Trial: 31563697
Drug: Low-dose gonadotropins
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol (Control Group A)
Trial: 27037817
Drug: Dexmedetomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine administered as short intravenous infusion of 1-2 µg/kg in 10 min
Trial: 11753959
Drug: Alternating chemoradiotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemoradiotherapy (ALT) - 4 cycles of intravenous cisplatin (20 mg/m² for 5 days) and 5-fluorouracil (200 mg/m² for 5 days) alternated with three 2-week courses of radiotherapy (20 Gy per course, 2 Gy per day, 5 days per week).